STOCKHOLM, SE / ACCESS Newswire / February 18, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference:

  • Location: Virtual

  • Format: Presentation and 1×1 meetings

  • Presentation Date and Time: Wednesday, February 25 at 4:00 PM EST

  • Webcast: Link

  • Participants: Ahmed Mousa, CEO, and Megan Richards, VP of IR and Comms

For more information, please contact:
Megan Richards, VP of IR and Comms, +1 978 269-4372, [email protected]
Hans Jeppsson, CFO, +46 70 553 14 65, [email protected]

About Vicore Pharma
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is a first-in-class oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.

Vicore is publicly listed on the Nasdaq Stockholm exchange with the ticker VICO. www.vicorepharma.com

SOURCE: Vicore Pharma Holding



View the original
on ACCESS Newswire


Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]